OPSONA-THERAPEUTICS-LTD
Opsona Therapeutics Ltd (‘Opsona’), the innate immune drug development company focused on novel therapeutic approaches to treat autoimmune, inflammatory diseases and oncology, today announced that the US Patent Office has issued US Patent 8,623,353, which covers an antibody directed against Toll-like Receptor-2 (TLR-2) and the use and development thereof.
TLR-2 plays an important role in the induction and progression of a number of non-pathogen associated inflammatory conditions including ischaemia reperfusion injury (delayed graft function in renal transplantation, myocardial infarct), certain cancer, autoimmune diseases, diabetes, Alzheimer's disease and atherosclerosis.
TLR-2 is one of the key structures of the innate immune system and is part of the first line defense against microbial organisms. Upon stimulation it induces and propagates inflammation. TLR-2 is activated through so called external danger signals (microbial cell wall components) as well as through so called internal danger signals resulting from tissue injury.
This patent describes a cross-reactive antibody which specifically blocks mammalian TLR-2 and further provides for a pharmaceutical composition for the treatment of various inflammatory conditions. The recently issued patent is assigned to the Technische Universitat Munchen (TUM) and Amgen Inc., and is exclusively licensed by Opsona Therapeutics.
Commenting on today's announcement, Mary Reilly VP Pharmaceutical Development and Operations of Opsona Therapeutics said, "The issuance of this patent is an important milestone in the development of Opsona's TLR2 intellectual property portfolio and will facilitate market exclusivity for the use of OPN-305 in the ever expanding area of TLR2 mediated diseases."
Using the TUM/Amgen license, Opsona has developed a clinical anti-TLR-2 antibody candidate, termed ‘OPN-305'. OPN-305 is a humanised IgG4 monoclonal antibody (mAb) antagonizing TLR-2 and is under development as a treatment for the prevention of Early Graft Dysfunction following renal transplantation and Myelodysplastic Syndromes (MDS), in addition to other therapeutic indications.
A three-part multi-center, double blinded and placebo controlled Phase II clinical study to evaluate the safety, tolerability and efficacy of OPN-305 in renal transplant patients at high risk of Early Graft Dysfunction as the first clinical target indication for the development of OPN-305 was initiated in April 2013 and is currently ongoing.
An open label Phase I/II study to assess the safety and efficacy of cycles of intravenously infused doses of OPN-305 in second-line lower (low and intermediate-1) risk MDS, a form of blood cancer, as the second clinical target indication for OPN-305 was initiated in January 2015.
-ends-
About Opsona Therapeutics
Opsona is a leading immunology drug development company, focused on novel therapeutic approaches to key targets of the innate immune system associated with a wide range of major human diseases, including autoimmune and inflammatory diseases, solid organ transplantation, cancer, diabetes, Alzheimer's disease and others. The company was founded in 2004 by three world-renowned immunologists at Trinity College in Dublin. Opsona have a strong international investor consortium including:
- Amgen Ventures (www.amgen.com/partners/amgen_ventures )
- Baxter Ventures (www.baxter.com/about_baxter/scientific_excellence/baxter_ventures )
- BB Biotech Ventures (www.bbbiotechventures.com )
- EMBL Ventures (www.embl-ventures.com )
- Enterprise Ireland (www.enterprise-ireland.com )
- Fountain Healthcare Partners (www.fh-partners.com )
- GenenFund (www.gene.com )
- Inventages Venture Capital (www.inventages.com )
- Novartis Venture Fund (www.nvfund.com )
- Omnes Capital (www.omnescapital.com )
- Roche Venture Fund (www.venturefund.roche.com )
- Seroba Kernel Life Sciences (www.seroba-kernel.com )
- Sunstone Capital (www.sunstone.eu )
Contact:
Opsona Therapeutics Ltd.
Mary Reilly
VP Pharmaceutical
Development and Operations
telephone: + 353 16770223
e-mail: MReilly@opsona.com
or
Martin
Welschof, CEO
telephone: + 353 16770223
mwelschof@opsona.com
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Regnology to Acquire Wolters Kluwer’s Finance, Risk & Regulatory Reporting Business Unit (FRR)21.7.2025 08:00:00 CEST | Press release
Expanding Regulatory Intelligence Platform and Global Reach Regnology, a leading software provider with a focus on regulatory reporting solutions, today announced it has entered into a definitive agreement to acquire Wolters Kluwer’s Finance, Risk & Regulatory Reporting (FRR) unit. The proposed acquisition represents a strategic step in Regnology’s ambition to deliver regulatory intelligence at scale—bringing together complementary capabilities across finance, risk, and regulatory reporting. It also expands Regnology’s presence in key markets and strengthens its ability to support financial institutions with granular data, jurisdiction-specific requirements, and cross-border compliance. Rob Mackay, CEO of Regnology, said: “FRR brings additional expertise and reach that will enhance our ability to serve clients globally. We look forward to supporting clients with a unified platform that helps them modernize their infrastructure, navigate Basel IV, and prepare for the future of regulator
EUMETSAT Takes Control of Europe’s First Geostationary Sounder Satellite21.7.2025 08:00:00 CEST | Press release
After more than two weeks of complex manoeuvring, precise positioning and meticulous checks, EUMETSAT assumed control of the Meteosat Third Generation Sounder 1 (MTG-S1) spacecraft on 18 July 2025, the latest addition to its fleet of geostationary meteorological satellites. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250720937880/en/ MTG-S1 in orbit Following MTG-S1’s successful launch on 1 July 2025, the satellite, which carries the Infrared Sounder (IRS) and the European Union’s Copernicus Sentinel-4 mission, has completed its launch and early operations phase (LEOP) and is now in orbit around 36,000km above the Equator at 3.4°W longitude. MTG-S1 will now begin months of intensive testing by experts at EUMETSAT with partners from the European Space Agency (ESA) and in industry to prepare for the delivery of vital data and products to specialists across EUMETSAT member states and beyond. Once fully commissioned, the sate
The Coca-Cola Company Names New Leader for Europe Operating Unit18.7.2025 21:00:00 CEST | Press release
The Coca-Cola Company today announced that Luisa Ortega will become president of the Europe operating unit effective Sept. 1, succeeding Nikos Koumettis, who will retire in 2026 after a 25-year career with the company. Koumettis will remain with the company through Feb. 28, 2026, as a senior advisor. He will also serve on the board of directors of Hindustan Coca-Cola Beverages Pvt. Ltd., a company-owned bottler in India. Ortega joined Coca-Cola in 2019 and currently serves as president of the Africa operating unit. In this role, she leads a complex business that operates across 54 markets. Koumettis has led the Europe operating unit since it was created in 2021. “Luisa has done an outstanding job leading our African business, where our system has continued to make major investments to serve growing markets on the continent,” said Henrique Braun, Executive Vice President and Chief Operating Officer of The Coca-Cola Company. “As head of Europe, she will bring great international experien
NFL Running Back Derrick Henry Joins Amazfit as Athlete Ambassador18.7.2025 15:00:00 CEST | Press release
Henry to utilize Amazfit products to optimize health, recovery and performance as he enters his 10th NFL season Amazfit, a leading global smart wearables brand owned by Zepp Health (NYSE: ZEPP), announced Baltimore Ravens running back Derrick Henry as the newest elite athlete to join its growing roster of ambassadors. Known for his rare combination of speed and strength, Henry will utilize Amazfit wearables to power every phase of his training, recovery and sleep as he prepares for his 10th NFL season. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250718322498/en/ Derrick Henry is the newest elite athlete to join Amazfit's growing roster of ambassadors. As one of the most prolific running backs of his generation, Henry has amassed an impressive array of accolades during his career, including NFL Offensive Player of the Year, two rushing titles, and five Pro Bowl selections. With Amazfit as his official smart wearable partne
Qualcomm Announces Quarterly Cash Dividend18.7.2025 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on September 25, 2025, to stockholders of record at the close of business on September 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensin
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum